The Impact of Telemedicine on Parkinson’s Care during the COVID-19 Pandemic: An Italian Online Survey
Abstract
:1. Introduction
2. Materials and Methods
2.1. Survey Development and Structure
2.2. Statistical Analysis
3. Results
3.1. PD Patients
3.1.1. Alternatives to In-Person Visits
3.1.2. Telemedicine
3.2. Neurologists
3.2.1. Alternatives to In-Person Visits
3.2.2. Telemedicine
4. Discussion
Limitations
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Government of Italy Decree of the President of the Council of Ministers 11 March 2020. Available online: https://www.gazzettaufficiale.it/eli/id/2020/03/11/20A01605/sg (accessed on 27 May 2021).
- Adams, M.L.; Katz, D.L.; Grandpre, J. Population-Based Estimates of Chronic Conditions Affecting Risk for Complications from Coronavirus Disease, United States. Emerg. Infect. Dis. 2020, 26, 1831–1833. [Google Scholar] [CrossRef] [PubMed]
- Helmich, R.C.; Bloem, B.R. The Impact of the COVID-19 Pandemic on Parkinson’s Disease: Hidden Sorrows and Emerging Opportunities. J. Parkinsons Dis. 2020, 10, 351–354. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- van der Heide, A.; Meinders, M.J.; Bloem, B.R.; Helmich, R.C. The Impact of the COVID-19 Pandemic on Psychological Distress, Physical Activity, and Symptom Severity in Parkinson’s Disease. J. Parkinsons Dis. 2020, 10, 1355–1364. [Google Scholar] [CrossRef] [PubMed]
- Weintraub, D.; Burn, D.J. Parkinson’s disease: The quintessential neuropsychiatric disorder. Mov. Disord. 2011, 26, 1022–1031. [Google Scholar] [CrossRef] [Green Version]
- Faccincani, R.; Pascucci, F.; Lennquist, S. How to Surge to Face the SARS-CoV-2 Outbreak: Lessons Learned From Lombardy, Italy. Disaster Med. Public Health Prep. 2020, 14, e39–e41. [Google Scholar] [CrossRef] [Green Version]
- Marcon, E.; Scotton, F.; Marcante, E.; Rigo, A.; Monticelli, J.; Buggio, M.E.; Pilerci, C.; Montemurro, D.; Benini, P. Schiavonia Hospital response to COVID-19 outbreak: A first single-center experience. Ann. Ist. Super. Sanita 2020, 56, 365–372. [Google Scholar] [CrossRef]
- Del Prete, E.; Francesconi, A.; Palermo, G.; Mazzucchi, S.; Frosini, D.; Morganti, R.; Coleschi, P.; Raglione, L.M.; Vanni, P.; Ramat, S.; et al. Prevalence and impact of COVID-19 in Parkinson’s disease: Evidence from a multi-center survey in Tuscany region. J. Neurol. 2021, 268, 1179–1187. [Google Scholar] [CrossRef]
- Kittleson, M.M. The Invisible Hand—Medical Care during the Pandemic. N. Engl. J. Med. 2020, 382, 1586–1587. [Google Scholar] [CrossRef]
- US Department of Health and Human Services. Health Resources & Services Adminstration: Telehealth Programs. 2018. Available online: https://www.hrsa.gov/rural-health/topics/telehealth#:~:text=HRSA’s%20focus%20is%20to%20improve,telehealth%20services%20in%20rural%20areas (accessed on 1 June 2022).
- Fasano, A.; Antonini, A.; Katzenschlager, R.; Krack, P.; Odin, P.; Evans, A.H.; Foltynie, T.; Volkmann, J.; Merello, M. Management of Advanced Therapies in Parkinson’s Disease Patients in Times of Humanitarian Crisis: The COVID-19 Experience. Mov. Disord. Clin. Pract. 2020, 7, 361–372. [Google Scholar] [CrossRef] [Green Version]
- Marotta, N.; Demeco, A.; Moggio, L.; Ammendolia, A. Why is telerehabilitation necessary? A pre-post COVID-19 comparative study of ICF activity and participation. J. Enabling Technol. 2021, 15, 117–121. [Google Scholar] [CrossRef]
- Mann, D.M.; Chen, J.; Chunara, R.; Testa, P.A.; Nov, O. COVID-19 transforms health care through telemedicine: Evidence from the field. J. Am. Med. Inform. Assoc. 2020, 27, 1132–1135. [Google Scholar] [CrossRef] [PubMed]
- van den Bergh, R.; Bloem, B.R.; Meinders, M.J.; Evers, L.J.W. The state of telemedicine for persons with Parkinson’s disease. Curr. Opin. Neurol. 2021, 34, 589–597. [Google Scholar] [CrossRef] [PubMed]
- Langbecker, D.; Caffery, L.J.; Gillespie, N.; Smith, A.C. Using survey methods in telehealth research: A practical guide. J. Telemed. Telecare 2017, 23, 770–779. [Google Scholar] [CrossRef] [PubMed]
- Federation of State Medical Boards. Guidelines for the Structure and Function of a State Medical and Osteopathic Board. Available online: https://www.fsmb.org/siteassets/advocacy/policies/guidelines-for-the-structure-and-function-of-a-state-medical-and-osteopathic-board.pdf (accessed on 1 June 2022).
- Mukaka, M.M. Statistics corner: A guide to appropriate use of correlation coefficient in medical research. Malawi Med. J. 2012, 24, 69–71. [Google Scholar] [PubMed]
- Miele, G.; Straccia, G.; Moccia, M.; Leocani, L.; Tedeschi, G.; Bonavita, S.; Lavorgna, L.; Padovani, A.; Clerico, M.; Brigo, F.; et al. Telemedicine in Parkinson’s Disease: How to Ensure Patient Needs and Continuity of Care at the Time of COVID-19 Pandemic. Telemed. J. E Health 2020, 26, 1533–1536. [Google Scholar] [CrossRef]
- Solimini, R.; Busardò, F.P.; Gibelli, F.; Sirignano, A.; Ricci, G. Ethical and Legal Challenges of Telemedicine in the Era of the COVID-19 Pandemic. Medicina 2021, 57, 1314. [Google Scholar] [CrossRef]
- Hassan, A.; Mari, Z.; Gatto, E.M.; Cardozo, A.; Youn, J.; Okubadejo, N.; Bajwa, J.A.; Shalash, A.; Fujioka, S.; Aldaajani, Z.; et al. Global Survey on Telemedicine Utilization for Movement Disorders During the COVID-19 Pandemic. Mov. Disord. 2020, 35, 1701–1711. [Google Scholar] [CrossRef]
- Shalash, A.; Spindler, M.; Cubo, E. Global Perspective on Telemedicine for Parkinson’s Disease. J. Parkinsons Dis. 2021, 11, S11–S18. [Google Scholar] [CrossRef]
- Abdolahi, A.; Scoglio, N.; Killoran, A.; Dorsey, E.R.; Biglan, K.M. Potential reliability and validity of a modified version of the Unified Parkinson’s Disease Rating Scale that could be administered remotely. Parkinsonism Relat. Disord. 2013, 19, 218–221. [Google Scholar] [CrossRef] [Green Version]
- Telemedicine in Your Movement Disorders Practice. Available online: https://www.movementdisorders.org/MDS/About/Committees--Other-Groups/Telemedicine-in-Your-Movement-Disorders-Practice-A-Step-by-Step-Guide.htm (accessed on 22 July 2020).
- Roumie, C.L.; Greevy, R.; Wallston, K.A.; Elasy, T.A.; Kaltenbach, L.; Kotter, K.; Dittus, R.S.; Speroff, T. Patient centered primary care is associated with patient hypertension medication adherence. J. Behav. Med. 2011, 34, 244–253. [Google Scholar] [CrossRef]
- Thompson, L.; McCabe, R. The effect of clinician-patient alliance and communication on treatment adherence in mental health care: A systematic review. BMC Psychiatry 2012, 12, 87. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bertakis, K.D.; Azari, R. Patient-centered care is associated with decreased health care utilization. J. Am. Board Fam. Med. 2011, 24, 229–239. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ekman, I.; Wolf, A.; Olsson, L.E.; Taft, C.; Dudas, K.; Schaufelberger, M.; Swedberg, K. Effects of person-centred care in patients with chronic heart failure: The PCC-HF study. Eur. Heart J. 2012, 33, 1112–1119. [Google Scholar] [CrossRef] [Green Version]
Indicators | Definition | Variables |
---|---|---|
satisfaction | subjective evaluation of whether the user’s expectations were met | -overall satisfaction -willingness to use/re-use |
experience | evaluation of the user’s experience of a healthcare service: the experience can be objective (e.g., waiting time) or subjective (e.g., level of patient-centredness) | -patient-reported experience measures -comfort -patient-centredness |
technical quality | subjective evaluation of the quality of the technology used | -audio and picture (video) -quality -reliability -usability/ease of use -intuitiveness/learnability -privacy and security |
effectiveness | objective/subjective assessment that a telehealth interaction helped improve the health status or well-being of a patient | -quality of life -change in health status -measures of health/well-being -patient empowerment -patient knowledge -patient-reported outcome measures |
usefulness/perceived usefulness | objective or subjective assessment that a telehealth interaction produced some benefit or met the purpose of the interaction | -convenience -time consequences -cost consequences -accessibility -effect on continuity of care -(future) intention to use -willingness to use/practice -acceptability |
effect on interaction | subjective assessment that the modality of communication affected clinician–patient or clinician–clinician interaction | -communication style -ease of communication -completeness of information |
Demographic Data | 197 Survey Respondents | 74 Alternatives to In-Person Visits Group | 27 Video Consultation Group | 20 Respondents to Video Consultation Constructs | |
---|---|---|---|---|---|
Mean ± SD | Mean ± SD | Mean ± SD | Mean ± SD | ||
age (years) | 65.65 ± 10.26 | 63.11 ± 10.15 | 60.63 ± 10.78 | 60.75 ± 11.12 | |
education (years) | 13.49 ± 3.93 | 13.72 ± 3.96 | 14.11 ± 3.75 | 14.5 ± 3.28 | |
disease duration (years) | 9.67 ± 6.66 | 9.65 ± 6.24 | 9.96 ± 7.36 | 9.05 ± 5.58 | |
n (%) | n (%) | n (%) | n (%) | ||
gender | male | 97 (49.24) | 33 (44.60) | 12 (44.44) | 10 (50) |
female | 100 (50.76) | 41 (55.40) | 15 (55.56) | 10 (50) | |
occupation | unemployed | 12 (6.09) | 10 (13.52) | 5 (18.52) | 4 (20) |
working | 46 (23.35) | 17 (22.97) | 7 (25.93) | 6 (30) | |
retired | 134 (68.02) | 45 (60.81) | 14 (51.85) | 10 (50) | |
other | 5 (2.54) | 2 (2.70) | 1 (3.70) | 0 (0) | |
area of residence | northern Italy | 120 (60.91) | 44 (59.46) | 16 (59.26) | 11 (55) |
central-southern Italy | 77 (39.09) | 30 (40.54) | 11 (40.74) | 9 (45) | |
home assistance | no | 21 (10.66) | 11 (14.86) | 5 (18.52) | 5 (25) |
yes | 176 (89.34) | 63 (85.14) | 22 (81.48) | 15 (75) | |
disease diagnosis | Parkinson’s disease | 168 (85.28) | 67 (90.54) | 27 (96.30) | 19 (95) |
atypical parkinsonisms | 29 (14.72) | 7 (9.46) | 0 (0) | 1 (5) | |
disease grade | slight | 48 (24.36) | 22 (29.73) | 11 (40.74) | 9 (45) |
mild | 27 (13.71) | 14 (18.92) | 6 (22.22) | 4 (20) | |
moderate | 60 (30.46) | 18 (24.32) | 6 (22.22) | 4 (20) | |
moderate-severe | 44 (22.33) | 15 (20.27) | 2 (7.41) | 1 (5) | |
severe | 18 (9.14) | 5 (6.76) | 2 (7.41) | 2 (10) | |
comorbidity | psychiatric symptoms | 13 (6.60) | 3 (4.05) | 0 (0) | 0 (0) |
cognitive impairment | 14 (7.11) | 5 (6.76) | 2 (7.41) | 1 (5) | |
none | 162 (82.23) | 64 (86.49) | 23 (85.19) | 18 (90) | |
psychiatric symptoms and cognitive impairment | 2 (1.02) | 1 (1.35) | 1 (3.70) | 1 (5) | |
na | 6 (3.04) | 1 (1.35) | 1 (3.70) | 0 (0) | |
previous use of telehealth | no | 170 (86.29) | 51 (68.92) | 19 (70.37) | 15 (75) |
yes | 27 (13.71) | 23 (31.08) | 8 (29.63) | 5 (25) | |
use of telehealth during COVID-19 | no | 123 (62.44) | 0 (0) | 0 (0) | 0 (0) |
yes | 74 (37.56) | 74 (100) | 27 (100) | 20 (100) | |
telehealth technical support | no | 47 (23.86) | 47 (63.51) | 14 (51.85) | 13 (65) |
yes | 26 (13.20) | 26 (35.14) | 13 (48.15) | 7 (35) | |
na | 124 (62.94) | 1 (1.35) | 0 (0) | 0 (0) | |
main reason(s) for consultation | follow up | 23 (11.68) | 23 (31.08) | 11 (40.74) | 7 (35) |
drug prescriptions | 11 (5.58) | 11 (14.86) | 5 (18.52) | 4 (20) | |
DBS parameters regulation | 2 (1.02) | 2 (2.70) | 0 (0) | 0 (0) | |
side-effect to drugs | 6 (3.04) | 6 (8.12) | 4 (14.81) | 3 (15) | |
other | 8 (4.06) | 8 (10.81) | 3 (11.12) | 3 (15) | |
mixed condition | 22 (11.17) | 22 (29.73) | 4 (14.81) | 3 (15) | |
na | 125 (63.45) | 2 (2.70) | 0 (0) | 0 (0) | |
telehealth suggested by | doctor | 46 (23.35) | 46 (62.16) | 20 (74.07) | 15 (75) |
patient’s associations | 9 (4.57) | 9 (12.16) | 5 (18.52) | 3 (15) | |
patients | 1 (0.51) | 1 (1.35) | 0 (0) | 0 (0) | |
internet | 5 (2.54) | 5 (6.76) | 0 (0) | 0 (0) | |
other | 12 (6.09) | 12 (16.22) | 2 (7.41) | 2 (10) | |
na | 124 (62.94) | 1 (1.35) | 0 (0) | 0 (0) | |
telehealth modality | none | 123 (62.44) | 0 (0) | 0 (0) | 0 (0) |
telephone | 10 (5.07) | 10 (13.52) | 0 (0) | 0 (0) | |
sms | 2 (1.02) | 2 (2.70) | 0 (0) | 0 (0) | |
chat | 1 (0.51) | 1 (1.35) | 0 (0) | 0 (0) | |
34 (17.25) | 34 (45.94) | 0 (0) | 0 (0) | ||
video consultation | 27 (13.71) | 27 (36.49) | 27 (100) | 20 (100) |
20 Patients | 17 Neurologists | ||
---|---|---|---|
n (%) | n (%) | ||
perceived usefulness | strongly disagree | 0 (0) | 0 (0) |
quite in disagreement | 1 (5) | 1 (5.88) | |
neither in agreement nor disagreement | 1 (5) | 3 (17.65) | |
quite in agreement | 5 (25) | 9 (52.94) | |
strongly agree | 13 (65) | 4 (23.53) | |
technical quality | strongly disagree | 0 (0) | 1 (5.88) |
quite in disagreement | 0 (0) | 1 (5.88) | |
neither in agreement nor disagreement | 2 (10) | 4 (23.53) | |
quite in agreement | 7 (35) | 7 (41.18) | |
strongly agree | 11 (55) | 4 (23.53) | |
effectiveness | strongly disagree | 0 (0) | 0 (0) |
quite in disagreement | 0 (0) | 1 (5.88) | |
neither in agreement nor disagreement | 3 (15) | 1 (5.88) | |
quite in agreement | 8 (40) | 11 (64.71) | |
strongly agree | 9 (45) | 4 (23.53) | |
effect on interaction | strongly disagree | 0 (0) | 0 (0) |
quite in disagreement | 1 (5) | 1 (5.88) | |
neither in agreement nor disagreement | 1 (5) | 1 (5.88) | |
quite in agreement | 7 (35) | 13 (76.47) | |
strongly agree | 11 (55) | 2 (11.76) | |
experience | strongly disagree | 0 (0) | 0 (0) |
quite in disagreement | 0 (0) | 0 (0) | |
neither in agreement nor disagreement | 2 (10) | 4 (23.53) | |
quite in agreement | 7 (35) | 9 (52.94) | |
strongly agree | 11 (55) | 4 (23.53) | |
satisfaction | strongly disagree | 0 (0) | 0 (0) |
quite in disagreement | 0 (0) | 0 (0) | |
neither in agreement nor disagreement | 2 (10) | 2 (11.76) | |
quite in agreement | 8 (40) | 12 (70.59) | |
strongly agree | 10 (50) | 3 (17.65) |
Usefulness/ Perceived Usefulness | Technical Quality | Effectiveness | Effect on Interaction | Experience | Satisfaction | |
---|---|---|---|---|---|---|
20 patients | ||||||
usefulness/perceived usefulness | - | ρ = 0.67 p = 0.001 | ρ = 0.67 p = 0.001 | ρ = 0.67 p = 0.001 | ρ = 0.67 p = 0.001 | ρ = 0.61 p = 0.004 |
technical quality | ρ = 0.67 p = 0.001 | - | ρ = 0.49 p = 0.029 | ρ = 0.54 p = 0.014 | ρ = 0.54 p = 0.014 | ρ = 0.58 p = 0.007 |
effectiveness | ρ = 0.67 p = 0.001 | ρ = 0.49 p = 0.029 | - | ρ = 0.84 * p < 0.001 | ρ = 0.84 * p < 0.001 | ρ = 0.74 * p < 0.001 |
effect on interaction | ρ = 0.67 p = 0.001 | ρ = 0.54 p = 0.014 | ρ = 0.84 * p < 0.001 | - | ρ = 0.99 * p < 0.001 | ρ = 0.89 * p < 0.001 |
experience | ρ = 0.67 p = 0.001 | ρ = 0.54 p = 0.014 | ρ = 0.84 * p < 0.001 | ρ = 0.99 * p < 0.001 | - | ρ = 0.89 * p < 0.001 |
satisfaction | ρ = 0.61 p = 0.004 | ρ = 0.58 p = 0.007 | ρ = 0.74 * p < 0.001 | ρ = 0.89 * p < 0.001 | ρ = 0.89 * p < 0.001 | - |
17 neurologists | ||||||
usefulness/perceived usefulness | - | ρ = 0.76 * p < 0.001 | ρ = 0.75 * p < 0.001 | ρ = 0.50 p = 0.041 | ρ = 0.76 * p < 0.001 | ρ = 0.65 p = 0.004 |
technical quality | ρ = 0.76 * p < 0.001 | - | ρ = 0.62 p = 0.008 | ρ = 0.37 p = 0.143 | ρ = 0.57 p = 0.017 | ρ = 0.41 p = 0.105 |
effectiveness | ρ = 0.75 * p < 0.001 | ρ = 0.62 p = 0.008 | - | ρ = 0.41 p = 0.103 | ρ = 0.73 * p = 0.001 | ρ = 0.37 p = 0.138 |
effect on interaction | ρ = 0.50 p = 0.041 | ρ = 0.37 p = 0.143 | ρ = 0.41 p = 0.103 | - | ρ = 0.71 * p = 0.002 | ρ = 0.69 * p = 0.002 |
experience | ρ = 0.76 * p < 0.001 | ρ = 0.57 p = 0.017 | ρ = 0.73 * p = 0.001 | ρ = 0.71 * p = 0.002 | - | ρ = 0.80 * p < 0.001 |
satisfaction | ρ = 0.65 p = 0.004 | ρ = 0.41 p = 0.105 | ρ = 0.37 p = 0.138 | ρ = 0.69 * p = 0.002 | ρ = 0.80 * p < 0.001 | - |
Demographic Data | 42 Survey Respondents | 37 Alternatives to In-Person Visits Group | 17 Video Consultation Group | |
---|---|---|---|---|
Mean ± SD | Mean ± SD | Mean ± SD | ||
age (years) | 50.55 (12.52) | 51.08 (11.15) | 52.47 (10.47) | |
n (%) | n (%) | n (%) | ||
gender | male | 19 (45.24) | 16 (43.24) | 8 (47.06) |
female | 23 (54.76) | 21 (56.76) | 9 (52.94) | |
working region | northern Italy | 31 (73.81) | 28 (75.68) | 14 (82.35) |
central-southern Italy | 11 (26.19) | 9 (24.32) | 3 (17.65) | |
working place | public hospital | 22 (52.38) | 21 (56.76) | 10 (58.82) |
private hospital | 4 (9.52) | 4 (10.81) | 2 (11.76) | |
private practice | 3 (7.14) | 3 (8.11) | 0 (0) | |
university | 5 (11.91) | 3 (8.11) | 1 (5.88) | |
other | 8 (19.05) | 6 (16.22) | 4 (23.53) | |
working experience (years) | 0–5 | 6 (14.28) | 4 (10.81) | 1 (5.88) |
6–15 | 11 (26.19) | 11 (29.73) | 5 (29.41) | |
16–25 | 10 (23.81) | 9 (24.32) | 4 (23.53) | |
26–35 | 8 (19.05) | 7 (18.92) | 5 (29.41) | |
>35 | 7 (16.67) | 6 (16.22) | 2 (11.76) | |
previous use of telehealth | no | 12 (28.57) | 7 (18.92) | 2 (11.76) |
yes | 30 (71.43) | 30 (81.08) | 15 (88.24) | |
use of telehealth during COVID-19 | no | 5 (11.90) | 0 (0) | 0 (0) |
yes | 37 (88.10) | 37 (100) | 17 (100) | |
telehealth suggested by | hospital | 14 (33.34) | 14 (37.84) | 7 (41.18) |
themselves | 16 (38.09) | 16 (43.24) | 7 (41.18) | |
patient | 5 (11.90) | 5 (13.51) | 3 (17.65) | |
na | 7 (16.67) | 2 (5.41) | 0 (0) | |
institutional platform | no | 23 (54.76) | 23 (62.16) | 9 (52.94) |
yes | 12 (28.57) | 12 (32.43) | 8 (47.06) | |
na | 7 (16.67) | 2 (5.41) | 0 (0) | |
telehealth technical support | no | 4 (9.52) | 4 (10.81) | 3 (17.65) |
yes | 7 (16.67) | 7 (18.92) | 5 (29.41) | |
na | 31 (73.81) | 26 (70.27) | 9 (52.94) | |
institutional guidelines | no | 6 (14.28) | 6 (16.22) | 5 (29.41) |
yes | 5 (11.90) | 5 (13.51) | 3 (17.65) | |
na | 31 (73.81) | 26 (70.27) | 9 (52.94) | |
main reason(s) for consultation | follow up | 4 (9.52) | 4 (10.81) | 3 (17.65) |
drug prescriptions | 2 (4.76) | 2 (5.41) | 1 (5.88) | |
DBS parameters regulation | 0 (0) | 0 (0) | 0 (0) | |
side-effect to drugs | 2 (4.76) | 2 (5.41) | 0 (0) | |
other | 0 (0) | 0 (0) | 0 (0) | |
mixed condition | 24 (57.14) | 24 (64.86) | 13 (76.47) | |
na | 10 (23.82) | 5 (13.51) | 0 (0) | |
telehealth modality | none | 0 (0) | 0 (0) | 0 (0) |
telephone | 2 (4.76) | 2 (5.41) | 0 (0) | |
sms | 0 (0) | 0 (0) | 0 (0) | |
chat | 1 (2.38) | 1 (2.70) | 0 (0) | |
12 (28.57) | 12 (32.43) | 0 (0) | ||
video consultation | 17 (40.48) | 17 (45.94) | 17 (100) | |
na | 10 (23.81) | 5 (13.51) | 0 (0) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ruggiero, F.; Lombi, L.; Molisso, M.T.; Fiore, G.; Zirone, E.; Ferrucci, R.; Pirola, E.; Locatelli, M.; Barbieri, S.; Mameli, F. The Impact of Telemedicine on Parkinson’s Care during the COVID-19 Pandemic: An Italian Online Survey. Healthcare 2022, 10, 1065. https://doi.org/10.3390/healthcare10061065
Ruggiero F, Lombi L, Molisso MT, Fiore G, Zirone E, Ferrucci R, Pirola E, Locatelli M, Barbieri S, Mameli F. The Impact of Telemedicine on Parkinson’s Care during the COVID-19 Pandemic: An Italian Online Survey. Healthcare. 2022; 10(6):1065. https://doi.org/10.3390/healthcare10061065
Chicago/Turabian StyleRuggiero, Fabiana, Linda Lombi, Maria Takeko Molisso, Giorgio Fiore, Eleonora Zirone, Roberta Ferrucci, Elena Pirola, Marco Locatelli, Sergio Barbieri, and Francesca Mameli. 2022. "The Impact of Telemedicine on Parkinson’s Care during the COVID-19 Pandemic: An Italian Online Survey" Healthcare 10, no. 6: 1065. https://doi.org/10.3390/healthcare10061065
APA StyleRuggiero, F., Lombi, L., Molisso, M. T., Fiore, G., Zirone, E., Ferrucci, R., Pirola, E., Locatelli, M., Barbieri, S., & Mameli, F. (2022). The Impact of Telemedicine on Parkinson’s Care during the COVID-19 Pandemic: An Italian Online Survey. Healthcare, 10(6), 1065. https://doi.org/10.3390/healthcare10061065